Ra Capital Management, L.P. Unicycive Therapeutics, Inc. Transaction History

Ra Capital Management, L.P.

  • $7.17 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$0.4 - $1.46 $1.05 Million - $3.84 Million
2,632,200 New
2,632,200 $1.32 Million
Q4 2023

Feb 14, 2024
BUY
$0.49 - $0.92 $1.7 Million - $3.19 Million
3,470,688 New
3,470,688 $3.02 Million
Q3 2023

Nov 14, 2023
BUY
$0.61 - $1.31 $2.12 Million - $4.55 Million
3,470,688 New
3,470,688 $2.98 Million

Others Institutions Holding UNCY

# of Institutions
31
Shares Held
46.8M
Call Options Held
0
Put Options Held
0
View Full List

About Unicycive Therapeutics, Inc.

UNCY Quotes by TradingView
  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $12.2M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Ra Capital Management, L.P. Portfolio

Follow Ra Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ra Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Ra Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email